<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02972268</url>
  </required_header>
  <id_info>
    <org_study_id>JLP-1207-P3</org_study_id>
    <nct_id>NCT02972268</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Compare the Solifenacin/Tamsulosin Combination Therapy With Tamsulosin Monotherapy for LUTS Due to BPH</brief_title>
  <official_title>Clinical Trial to Compare the Efficacy and Safety of Solifenacin/Tamsulosin Combination Therapy With Tamsulosin Monotherapy for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeil Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jeil Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical Trial to Compare the Efficacy and Safety of Solifenacin/Tamsulosin Combination
      Therapy with Tamsulosin Monotherapy for Lower Urinary Tract Symptoms due to Benign Prostatic
      Hyperplasia
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of TUFS</measure>
    <time_frame>12 weeks from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>change of total IPSS</measure>
    <time_frame>12 weeks from baseline</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">734</enrollment>
  <condition>Lower Urinary Tract Symptoms</condition>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tamsulosin 0.2mg + Solifenacin 5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tamsulosin 0.2mg + Placebo(Solifenacin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin 0.2mg + Solifenacin 5mg</intervention_name>
    <description>Tamsulosin 0.2mg + Solifenacin 5mg for 12wks</description>
    <arm_group_label>Group I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin 0.2mg + Placebo(Solifenacin)</intervention_name>
    <description>Tamsulosin 0.2mg + Placebo(Solifenacin) for 12wks</description>
    <arm_group_label>Group II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Over 45 years

          -  Benign Prostate Hyperplasia diagnosed by 20 mL &lt; TRUS

          -  Lower urinary tract symptom suggestive of benign prostate hyperplasia, who
             spontaneously agree to join and sign to the consent form

        Exclusion Criteria:

          -  Subjects who have a history of the lower urinary tract cancer, including prostate
             cancer and bladder cancer within the past 3 years

          -  Subjects who have acute urinary retention within 12 weeks before screening

          -  Subjects who have clinically significant severe cardiovascular disease(unstable
             angina, myocardial infarction or arrhythmia) within 24 weeks before screening

          -  Subjects who have hypersensitivity to investigational product

          -  Subjects who were suspected or confirmed neurogenic bladder, bladder neck structure,
             bladder diverticulum

          -  Subjects who have myasthenia gravis, narrow angle glaucoma

          -  Subjects who have hereditary problems of galactose intolerance, Lapp lactase
             deficiency or glucose-galactose malabsorption

          -  SBP &gt; 180 mmHg or DBP &gt; 100 mmHg

          -  HbA1c &gt; 9.0 %

          -  Subjects who are judged by the investigators to be unsuitable to participate in the
             clinical trial.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myung Soo Choo, MD., Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yong Woo Lee, MSc</last_name>
    <email>ywlee97@jeilpharm.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myung Soo Choo, MD., Ph.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2016</study_first_submitted>
  <study_first_submitted_qc>November 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2016</study_first_posted>
  <last_update_submitted>November 22, 2016</last_update_submitted>
  <last_update_submitted_qc>November 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
    <mesh_term>Solifenacin Succinate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

